tumor types [1] [2] [3] . Some of these transcription factors are expressed in normal adult tissues at a level similar to their expression in tumors [4] ; thus, their potential as therapeutic targets is unknown at this time.
The transcription factor brachyury was initially identified as a molecule relevant to the formation of the mesoderm during murine embryonic development, which involves conversion of epithelial cells into mesenchymal cells [5] . It is thus a mediator of a normal physiologic EMT. Subsequent studies revealed brachyury to be expressed in a range of human tumors, with limited levels in human adult testes and thyroid, and little or no expression in other normal adult tissues [4, 6] . In vitro studies showed that high levels of brachyury expression in a range of human carcinoma cells correlated with a more mesenchymal/fibroblastoid morphology, ability to migrate and invade in in vitro assays, and expression of the mesenchymal markers [7] ; silencing of brachyury led to a reversion of these phenomena [7] [8] [9] [10] . These and other studies have defined brachyury as a master driver of EMT in human carcinomas. Analyses of cloned populations of human carcinoma cells have shown brachyury to be associated with drug resistance [10] .
Brachyury expression has been demonstrated in a number of carcinomas, but the expression levels vary by tumor type. Studies of biopsy specimens of human lung carcinomas have shown brachyury to be expressed at higher levels in high-grade lesions [9] . Immunohistochemistry (IHC) studies of human breast carcinoma lesions using a brachyury-specific monoclonal antibody have shown low to moderate brachyury expression in primary tumors with a high level of expression in regional lymph node and distal metastases, and brachyury expression was associated with poor prognosis [11] . High levels of brachyury expression have also been associated with poor prognosis of lung [12] , prostate [13] and colon [14] carcinomas, and with tamoxifen resistance in breast carcinomas [11] . High levels of brachyury have also been found in human chordomas [15] .
Transcription factors such as brachyury, however, are generally believed to be difficult to target with small molecule targeted therapies due to their nuclear location and lack of a specific groove for the tight binding of a small molecule inhibitor. An alternative approach to target transcription factors is vaccine-mediated T-cell therapy. Previous studies have identified an HLA-A2 class I brachyury peptide that is capable of inducing human CD8 + cytotoxic T lymphocytes (CTL) in vitro [6] ; these T cells were shown to be capable of selectively lysing a range of brachyury expressing human carcinoma cell lines [6] . These studies demonstrated that brachyury polypeptides are transported through the cytoplasm to the cell surface in the context of 9-10 mer peptide-major histocompatibility complex (MHC) class I complexes for T-cell recognition. While class I HLA-A2 peptides restrict their use to HLA-A2 positive patients, this allele is present in approximately 50 % of the Caucasian population [16] .
A heat-killed recombinant Saccharomyces cerevisiae (yeast) vaccine expressing brachyury has also been developed that expresses the entire brachyury protein and can activate both human brachyury-specific CD8 + and CD4 + T cells in vitro [17] . This vaccine is being evaluated in a phase I clinical trial in patients with advanced cancers (NCT01519817) [18] [19] [20] . Subsequent to these studies, an effort was undertaken to enhance the endogenous immunogenicity of brachyury. One way to accomplish this is to alter the amino acid anchor residue of a 9-to 10-mer peptide to strengthen its binding to the MHC-class I molecule [21, 22] . Such enhancer agonist epitopes must be capable of augmenting T-cell functions such as cytokine production over the native epitope; more importantly, T cells activated with the agonist must also recognize the native epitope endogenously expressed on tumor cells and be able to lyse these cells. The studies reported here describe the identification of a brachyury agonist epitope that is capable of enhancing the generation and activation of brachyury-specific CD8 + T cells. Also reported is the characterization of a heat-killed recombinant yeast vector expressing the whole brachyury gene and containing the brachyury enhancer epitope. These studies provide the rationale for the potential use of the agonist epitope in peptide-based vaccines, a recombinant yeast vaccine, other vaccine platforms, or engineered T cells targeting brachyury.
Materials and methods

Patients
For the establishment of brachyury peptide-specific T-cell lines, we utilized peripheral blood mononuclear cells (PBMCs) from two patients (patients #1 and #2) with prostate cancer enrolled in a previously described clinical trial of PSA-TRICOM vaccine in combination with ipilimumab (NCT00113984) [23, 24] . An institutional review board of the National Institutes of Health (NIH) Clinical Center had approved the procedures, and informed consent was obtained in accordance with the Declaration of Helsinki.
Cell culture
The human pancreatic carcinoma cell lines CFPAC-1 and ASPC-1, the human lung cancer cell line H441, the human colon carcinoma cell line SW620, and the human breast carcinoma cell line MDA-MB-231 were purchased from American Type Culture Collection (ATCC) (Manassas, VA). The cultures were free of Mycoplasma and were maintained as recommended by ATCC. K562/A2.1, a human myelogenous leukemia cell line that expresses a transfected genomic clone of HLA-A2.1, was obtained from C. Britten (Johannes Gutenberg-University of Mainz, Mainz, Germany) [25] . The transport deletion mutant cell line T2 transfected with the HLA-A2 gene was provided by Dr. Peter Cresswell (Yale University School of Medicine, New Haven, CT) [26] . K562/A2.1 and T2 cells were Mycoplasma free and were maintained in RPMI 1640 complete medium and in Iscove's modified Dulbecco's complete medium [supplemented with 10 % fetal bovine serum, 2 mM glutamine, 100 units/ ml penicillin, and 100 μg/ml streptomycin (Invitrogen Life Technologies, Inc, Carlsbad, CA)], respectively.
Peptides
The 9-mer brachyury HLA-A2 binding peptide (WLLPGT-STL), herein called "native," had been previously identified and evaluated for binding and stability [6] . An agonist peptide, designated "agonist," was produced by changing the anchor residue at position 254 from leucine to valine, increasing the predicted one-half-time dissociation of the peptide/MHC complex according to the BIMAS algorithm [27] (Fig. 1a) . Peptides were synthesized at >95 % purity by CPC Scientific (Sunnyvale, CA).
Peptide binding and stability
Peptide binding and stability were evaluated by the accumulation of HLA-A2 on the surface of T2 cells as determined by an increase in the mean fluorescence intensity (MFI) [28] . HLA-A2 binding peptide NGEP [29] and an HLA-A3 binding peptide served as positive and negative controls, respectively. Samples were run on a BD FACScan and analyzed with CellQuest software (BD). For the stability assay, the percentage of remaining peptide-MHC complexes was calculated by dividing the MFI at each time point by the initial MFI (time point 0 = 100 %).
Saccharomyces cerevisiae (yeast) vector
Saccharomyces cerevisiae (yeast) were transfected with a plasmid expressing full-length brachyury with or without the substitution of leucine to valine at position 254 (GlobeImmune, Louisville, CO).
Culture of dendritic cells from PBMCs
HLA-A2 healthy donor PBMCs were obtained from heparinized blood. PBMCs were separated using lymphocyte separation medium gradient (Organon Teknika, Durham, NC), according to the manufacturer's instructions. Dendritic cells (DCs) were prepared from PBMCs as previously described [30] .
Generation of T-cell lines
Peptide-generated T-cell lines
A modification of the protocol described by Tsang et al. [31, 32] was used to generate brachyury-specific CTL. IFN-γ production by T-cell cultures was measured using a human IFN-γ ELISA kit (Invitrogen, Grand Island, NY), 24 h after restimulation.
Yeast-generated T-cell lines
A modification of the protocol described by Remondo et al. [33] was used to generate brachyury-specific CTL using yeast. Autologous DCs were incubated with yeast at a 1:1 ratio for 48 h. The culture was gently rinsed to remove excess yeast, and PBMCs were added at an effector-to-APC ratio of 10:1. Irradiated autologous EBV-transformed B cells pulsed with the corresponding peptide were used as APCs after the third IVS cycle.
T-cell phenotyping
The brachyury agonist-specific T-cell lines were examined for antigen-specificity and perforin production. T cells (2 × 10 5 ) were stained with FITC-conjugated anti-CD8 (BD) and either a PE-conjugated agonist-specific tetramer (NIH Tetramer Core Facility, Atlanta, GA) or a negative control tetramer (Beckman Coulter, Fullerton, CA). Cells stained for perforin production were surface stained with FITC-conjugated anti-CD8 (BD) and then permeabilized using a Fixation/Permeabilization kit (eBioscience, San Diego, CA) according to the manufacturer's instructions. Cells then underwent intracellular staining with PE-conjugated anti-perforin antibody or isotype control (BD). In addition, T-cell lines were stained with CD8-V421 (BD), CD45RA-PerCP-Cy5. 5 (eBioscience), CCR7-AF700 (R&D Systems, Minneapolis, MN), CD27-PE (BD), Perforin-APC (BioLegend, San Diego, CA) and Ki67-FITC (BD), and 1x10 5 cells were captured on an LSRII (BD) and analyzed using FlowJo 9.0.1 software (Tree Star Inc, Ashland, OR).
Cytotoxicity assay
Cytotoxicity assays were performed as previously described [34] . For cold target inhibition, K562/A2.1 cells were treated with or without 20 µg/ml of agonist peptide for 2 h and then added at a 10:1 ratio with the targets. Antibody-blocking experiments were performed by pre-treating target cells with 10 µg/ml of anti-HLA-A2 antibody or isotype control UPC-10 for 1 h.
Immunizations, in vitro cytotoxicity assay, and cytokine release assay Adult female A2.1/K b transgenic mice [35] were vaccinated s.c. 3× weekly with 100 µl Montanide ISA VG 51 emulsion (Seppic, Fairfield, NJ) containing 0, 10, 50, or 100 µg brachyury agonist or native peptide. Two weeks after the final vaccination, two spleens were harvested and pooled from each vaccination group. Single-cell suspensions were prepared and grown for 6 days in complete RPMI containing 10 µg/ml of the immunizing peptide. These cells were then co-incubated in round-bottomed 96-well plates with 111 In-labeled, A2.1/K b -expressing Jurkat cells [36] pulsed with 10 µg/ml of brachyury agonist, brachyury native, or control peptide (CMV pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] or influenza M1 58-66 ). After overnight incubation, a Wizard 2 gamma counter (PerkinElmer) was used to measure 111 In release. Cytotoxicity was calculated as % specific lysis = [(experimental cpm − spontaneous cpm)/(total cpm − spontaneous cpm)] × 100. Results from triplicate wells were combined and reported as mean ± SEM. Unused effector cells were placed in complete RPMI overnight without peptide and then restimulated with 10 µg/ml of the same brachyury or control peptides. Each restimulation culture consisted of 2 × 10 5 effector cells, 1 × 10 6 naïve A2.1/K b transgenic mouse splenocytes as APCs (irradiated at 20 Gy), and 10 µg/ml peptide in 1 ml complete RPMI. Supernatant samples were collected after 2 days, centrifuged to remove contaminating cells, and then tested for mouse IFN-γ levels using a standard ELISA kit (Thermo Scientific, Waltham, MA).
Results
The predicted and actual binding to T2 cells of the previously described [6] native (Tp2) brachyury 9-mer HLA class I binding peptide (WLLPGTSTL) is shown in Fig. 1a , b. Modification of a single amino acid at the position 9 anchor residue from leucine (L) to valine (V) (WLLPGTSTV) predicted a greater binding to HLA-A2 class I (Fig. 1a) [27] . The actual binding assay to T2 cells revealed an increased T2 binding of the agonist peptide (Fig. 1b) . A comparison of the sequences of the native and agonist epitopes in a protein database [Basic local alignment search tool (BLAST)] showed similar results for both peptides, with 100 % homology to the brachyury protein, and not to other proteins in the database. Titration of the native and agonist peptides for binding to T2 cells from 25 to 1.65 µg/ml (twofold dilutions) showed greater binding of the potential agonist at each concentration. To determine the HLA-A2 "off rate," i.e., avidity of each peptide, T2 cells were incubated with each peptide for 18 h, then treated with brefeldin A (BFA) and analyzed by flow cytometry at various time points to detect the presence of surface peptide-HLA-A2 complexes. As seen in Fig. 1c , the agonist peptide was more stable at each time point than the native peptide (P = 0.045 for ROC curve analysis).
Functional studies of the peptides were initiated by determining the ability of each to activate T cells to produce IFN-γ. A CD8 + T-cell line was generated from PBMCs from a prostate cancer patient previously vaccinated with PSA-TRICOM vaccine and ipilimumab [23] by pulsing autologous DCs with the native brachyury peptide. As seen in Fig. 2a , DCs pulsed with agonist peptide were more efficient than DCs pulsed with the native peptide at activating T cells to produce IFN-γ at each peptide concentration. Approximately tenfold less agonist peptide than the native peptide enabled T-cell IFN-γ production of 100 pg/ml. A T-cell line from the same prostate cancer patient was then generated with the agonist peptide, using the same methods. As seen in Fig. 2b , DCs pulsed with the agonist peptide again elicited higher levels of IFN-γ from the T-cell line than DCs pulsed with the native peptide. A tetramer generated against the agonist peptide showed 66 % binding of CD8 + T cells generated with the agonist peptide vs. 0.47 % binding to control tetramer (Fig. 2b,  insert) .
Previous studies [6, 17] have shown that human T-cell lines generated using the native peptide have the ability to lyse a variety of brachyury positive, HLA-A2 positive human carcinoma lines. The two T-cell lines generated in the present study using the native and agonist peptides were then analyzed for the ability to lyse human carcinoma cells endogenously expressing the native brachyury epitope. While some lysis was seen against the CFPAC-1 human pancreatic carcinoma cell line (brachyury + , HLA-A2 + ) using the T-cell line generated with the native peptide, a higher degree of lysis was seen using the T-cell line generated using the agonist peptide (Fig. 3a) . As an indication of the MHC-restricted character of their cytotoxic function, both T-cell lines were unable to lyse the ASPC1 pancreatic carcinoma line (brachyury + , HLA-A2 neg ) (Fig. 3b) . The T-cell line generated using the agonist peptide was also able to efficiently lyse the human lung carcinoma line H441 (Fig. 3c ) and the human colon carcinoma line SW620 (Fig. 3d) , both of which are brachyury + , HLA-A2 + . Brachyury expression in these tumor cell lines had previously been evaluated by RT-PCR [6] .
Cold target inhibition studies were conducted to validate the nature of the HLA-A2 restriction of the lysis observed with the agonist peptide-derived T-cell line. The lysis of both the H441 lung carcinoma line and the CFPAC-1 pancreatic carcinoma line was inhibited by the addition of K562/A2.1 cells exposed to peptide, with no appreciable reduction in lysis when the K562/A2.1 cells were not exposed to peptide (Fig. 3e) . The lysis of CFPAC-1 and the human breast carcinoma line MDA-MB-231 (brachyury + , HLA-A2 + ) could be specifically inhibited by the addition of anti-HLA-A2 monoclonal antibody (Fig. 3f) , thus providing additional evidence for the MHC-class I A2 restriction of the lysis, and that T cells generated using the agonist peptide could lyse tumor cells endogenously expressing the native epitope. Studies were then conducted to better examine the differences that may exist in the generation of a human CD8 + T-cell line from the same individual and at the same time using APCs pulsed with either the native or agonist brachyury peptide. As seen in the middle row of Fig. 4 , the T-cell line generated with the native peptide and stimulated with the native peptide showed 6.2 % Ki67 positive CD8 + T cells, while the same cell line stimulated with the agonist peptide showed 10.4 % Ki67 positive
CD8
+ T cells, indicating a higher degree of proliferation when stimulated with the agonist vs. native peptide. The T-cell line generated with the agonist peptide and stimulated with that same peptide had a fivefold increase in Ki67 positive cells compared to the T-cell line generated and stimulated with the native peptide (Fig. 4, middle  row) . Similar findings were observed with regard to the levels of perforin (Fig. 4, top row) , revealing more cells with higher potential lytic activity when T cells are either + / CD27
+ cells than CD8 + T cells generated and stimulated with the native peptide. There is evidence that the loss of CD27 from CD45RA + T EMRA cells is a terminal differentiation event that correlates with loss of telomerase activity and telomere shortening [37, 38] . The presence of a significant population of Ki67 + /CD45RA + /CD27 + T cells thus suggests that the highly proliferative population induced by stimulation with the agonist peptide is not a terminally differentiated effector population, but rather a population that can maintain proliferative potential to expand the pool of antigen-specific effectors.
In order to investigate the immunogenicity of the brachyury agonist in vivo, A2.1/K b transgenic mice were vaccinated three times weekly with the agonist or native peptide mixed with the vaccine adjuvant Montanide. Splenocytes from mice vaccinated with the brachyury agonist peptide were highly cytotoxic against Jurkat target cells (A2.1/K b +) pulsed with the agonist peptide (Fig. 5a) . Those same T cells also recognized to a lesser extent target cells pulsed with the native brachyury peptide; two viral-derived peptides were used as controls (Fig. 5a) . Splenocytes from mice vaccinated with Montanide   Fig. 4 Phenotypic analysis of brachyury native and agonist peptidegenerated T-cell lines. T-cell lines were generated with brachyury native and agonist peptides from the same patient #2 with prostate cancer and were designated T(native) and T(agonist), respectively. At IVS 5 T(native) was stimulated with either native or agonist peptide, and T(agonist) was stimulated with agonist peptide. On day 5 after stimulation, phenotypic analysis by flow cytometry was performed. The experiment was repeated three times, and representative FACS plots are shown. For the first two rows, cells were first gated on CD8 + and the percent positive out of the CD8 gate is shown in each plot. For the third row, cells were first gated on CD8 +
/Ki67
+ /CCR7 neg and the percent positive shown is of total CD8 mixed with native brachyury peptide (Fig. 5b) failed to lyse targets in a peptide-specific manner. Splenic T cells from mice vaccinated with the agonist peptide (Fig. 5c ) produced much higher levels of IFN-γ than T cells from mice vaccinated with the native peptide (Fig. 5d) . For the native peptide, stimulation with 100 µg of either peptide resulted in lower levels of IFN-γ than stimulation with 50 µg of peptide, and this is most likely due to overactivation of the T cells. Furthermore, the agonist peptide consistently reactivated T cells from agonist peptidevaccinated mice more strongly than the native peptide. Taken together, these results indicate that the brachyury agonist peptide activates T cells in vivo and in vitro more effectively than the native peptide.
We have recently characterized in preclinical studies a heat-killed recombinant S. cerevisiae (yeast) brachyury vaccine [17] . A recombinant yeast brachyury vector has now been constructed that transcribes the entire brachyury gene with the residue change at position 254 to create the agonist epitope. As shown in Table 1 , DCs derived from the same donor were exposed to either recombinant yeast (native) containing the entire brachyury gene with the native epitope, or recombinant yeast (agonist), which means it contains the brachyury gene encoding the agonist epitope. Yeast (control) is wild-type yeast containing no brachyury protein. As seen in Table 1a , at each yeast/ DC ratio the yeast (agonist) was more efficient in activating brachyury-specific T cells originally generated with the native peptide to produce IFN-γ. The same phenomenon was observed employing the activation of brachyuryspecific T cells from the same individual, but derived using the agonist epitope (Table 1b) . There was approximately a five-to eightfold increase in the IFN-γ production of T cells if they were derived from DCs pulsed with agonist epitope and stimulated with the yeast (agonist) compared to T cells derived from DCs pulsed with the native epitope and stimulated with the yeast (native). Control yeast did not stimulate the brachyury-specific T-cell lines to produce IFN-γ. (Fig. 3g) . The same T-cell line also showed the ability to lyse human breast carcinoma cells (MDA-MB-231, brachyury + , HLA-A2 + ) but not the brachyury + , HLA-A2 neg pancreatic carcinoma cell line ASPC-1 (Fig. 3h) , indicating the MHC HLA-A2 class I restriction of the lysis.
Discussion
It should be noted that the development of an enhancer agonist epitope is not as simple as producing a peptide with altered binding affinity based on computer algorithms. Recent studies in our laboratory have shown [32] that some potential "agonist" peptides with the highest predicted binding to MHC-class I HLA-A2 (a) can have relatively poor HLA-A2 binding in in vitro assays, (b) cannot activate T cells to induce IFN-γ, and/or (c) cannot generate T cells that lyse tumor cells endogenously expressing the native antigen. Some predicted "agonist" epitopes have also demonstrated antagonist activity. There is always the possibility that a novel agonist epitope will not cross-react with the native epitope endogenously expressed on tumor cells. Here, we have shown that four different human tumor cell lines that endogenously express the native epitope are lysed by the agonist-specific T cells, so indeed these T cells recognize and bind the native epitope. In addition, the lysis of tumor cells expressing the native epitope could be blocked by the addition of K562/A2.1 cells pulsed with the agonist epitope (see Fig. 3e ). In making the agonist epitope, we also did not alter the T-cell receptor, only the affinity for HLA-A2.
We have previously shown that tumor cells that express no brachyury cannot be lysed by brachyury-specific T cells [6] . However, there is not always a direct correlation between the amount of brachyury expression and the degree of CTL lysis when using different tumor cell lines. Other factors have been shown previously to be involved in T-cell killing of tumor cells, such as (a) HLA class I level on tumor, (b) level and/or presence of accessory molecules such as Fas and ICAM, and (c) processing of peptide via transporter molecules to peptide-MHC complexes. Also, we have recently shown [39] that extremely high levels of brachyury in some tumor cell lines result in resistance to killing by chemotherapeutic agents and immune attack.
The studies reported here provide the rationale to employ the agonist brachyury epitope in a range of vaccine modalities. The agonist peptide described here can be used with (a) dendritic cell vaccines, (b) as transgenes in viral, bacterial or yeast vector vaccines, (c) conventional or experimental adjuvants, (d) for the in vitro activation of T cells for adoptive T-cell transfer protocols, (e) for T-cell receptor genetically engineered T cells for adoptive transfer protocols, or (f) in protein-or polypeptide-based vaccines.
The studies reported here also demonstrate that the brachyury agonist epitope can be appropriately processed and expressed in the context of a peptide-MHC complex by human DCs exposed to the recombinant yeast brachyury vector to activate brachyury-specific T cells. As shown, compared to the native epitope, both the brachyury agonist peptide and the brachyury agonist yeast vector can generate T cells capable of enhanced IFN-γ production and lysis of tumor cells endogenously expressing the native epitope.
Previous studies have shown that recombinant yeast is relatively easy to engineer, produce and purify. They contain the recombinant protein, are heat-killed, and are thus relatively safe compared to other forms of cancer therapy [40] . Previous studies have shown that recombinant yeast are efficiently taken up by human or murine DCs, which are consequently matured to express high levels of costimulatory molecules and produce high levels of type I cytokines [41, 42] . Preclinical studies have shown that yeast-CEA can activate human CD8 + and CD4 + T cells in vitro, and show 1 3
anti-tumor activity versus CEA-expressing murine tumors [33, 42] . A Phase I trial with recombinant yeast-CEA has been completed [40] , and a Phase II trial is ongoing in patients with medullary thyroid cancer (NCT01856920) [43] . Using either the native or agonist peptides, or yeast constructs containing these epitopes, we have generated CD8 + T-cell lines specific for the brachyury peptides. This was accomplished using PBMCs from both healthy donors and cancer patients. Specific T-cell lines were generated from PBMCs from 4/9 healthy donors and 5/5 cancer patients using the brachyury yeast constructs, and 3/6 healthy donors and 8/8 cancer patients using the brachyury peptides. In total, brachyury-specific CD8 + T-cell lines were generated from 9/14 individuals with brachyury yeast, and 11/14 individuals with brachyury peptides. Thus, no difference was seen. However, since the yeast-brachyury constructs express the entire brachyury protein, we were also able to generate brachyury-specific CD4 + T cells from 3/9 healthy donors using the yeast-brachyury constructs.
Previous clinical trials with a CEA-based vaccine and a PSA-based vaccine have revealed that patients mounted a post-vaccination brachyury-specific CD8
+ response not seen pre-vaccination [23, 40] . This may be the result of cross-priming of brachyury from lysed tumor cells to antigen-presenting cells. These studies, however, provide additional evidence of the potential immunogenicity of brachyury in humans. The studies described here provide the rationale for the use of the brachyury agonist epitope to enhance the immunogenicity of brachyury in the use of a range of anticancer vaccine strategies.
